MP-1000
- Generic Name
- MP-1000
MP1032 Treatment in Patients With Moderate to Severe COVID-19
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- MetrioPharm AG
- Target Recruit Count
- 132
- Registration Number
- NCT04932941
- Locations
- 🇧🇬
MHAT Sv. Ivan Rilski Kozloduy, Kozloduy, Bulgaria
🇺🇸Snake River Research PLLC, Idaho Falls, Idaho, United States
🇺🇸Richmond University Medical Center, Staten Island, New York, United States
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- MetrioPharm AG
- Target Recruit Count
- 155
- Registration Number
- NCT03706209
- Locations
- 🇩🇪
Klinische Forschung Dresden GmbH, Dresden, Germany
🇵🇱Kliniczny Szpital Wojewódzki nr 1 im. Fryderyka Chopina w Rzeszowie, Klinika Dermatologii, Rzeszów, Poland
🇩🇪MensingDerma, Hamburg, Germany
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- MetrioPharm AG
- Target Recruit Count
- 46
- Registration Number
- NCT02908347
- Locations
- 🇩🇪
PAREXEL International GmbH, Klinikum Westend, Berlin, Germany
🇩🇪Klinische Forschung Dresden GmbH, Dresden, Germany
🇩🇪Gemeinschaftspraxis Prof. Dr. Vanscheidt und Dr. Ukat, Freiburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath